Drug Profile
BR 4001
Alternative Names: BR-4001Latest Information Update: 23 Mar 2022
Price :
$50
*
At a glance
- Originator Boryung Pharmaceutical
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 31 Jan 2022 Discontinued - Phase-III for Alzheimer's disease in South Korea (Boryung Pharmaceutical pipeline, January 2022)
- 20 May 2020 Phase-III clinical trials for Alzheimer's disease in South Korea (unspecified route), prior to May 2020 (Boryung Pharmaceutical pipeline, May 2020)
- 06 Apr 2018 Phase-I clinical trials in Alzheimer's disease in South Korea (unspecified route) (Boryung Pharmaceutical pipeline, April 2018)